CRISPR-phage antibacterials to address the antibiotic resistance crisis: scientific, economic, and regulatory considerations
Research output: Contribution to journal › Journal article › Research › peer-review
Antibiotic resistance is one of the most dangerous threats to public health. The use of viruses to kill bacteria—phage therapy—has been used for nearly a century but has only recently risen to the forefront of discussion as a potential non-traditional antibacterial that can help to address antibiotic resistant infections. Phage therapy can be augmented using CRISPR (clustered regularly interspaced short palindromic repeats) for tailored bacterial killing. This article assesses the potential of CRISPR-enhanced phage therapy as a product that can address antibiotic resistance, focusing on the economic, legal, and regulatory challenges to its development and availability
Original language | English |
---|---|
Article number | lsad030 |
Journal | Journal of Law and the Biosciences |
Volume | 11 |
Issue number | 1 |
ISSN | 2053-9711 |
DOIs | |
Publication status | Published - 1 Jan 2024 |
Bibliographical note
Funding Information:
Timo Minssen’s and Jonathan J. Darrow’s research for this paper was supported by a Novo Nordisk Foundation Grant for a scientifically independent International Collaborative Bioscience Innovation & Law Programme (Inter-CeBIL programme - grant no. NNF23SA0087056). Jonathan J. Darrow also received funding from Arnold Ventures.
- antibacterials, CRISPR, CRISPR-phage, individualized therapies, new genomic technologies, phage therapies, public health
Research areas
ID: 386669784